Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation

Antimicrobial treatment in critically ill patients remains challenging. The aim of this study was to develop a population pharmacokinetic model for linezolid in critically ill patients and to evaluate the adequacy of current dosing recommendation (600 mg/12 h). Forty inpatients were included, 23 of...

Descripción completa

Detalles Bibliográficos
Autores: Soraluce Olañeta, Amaia, Barrasa González, Helena, Asín-Prieto, Eduardo, Sánchez Izquierdo, José Ángel, Maynar, Javier, Isla Ruiz, Arantxazu, Rodríguez Gascón, Alicia
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad del País Vasco
Repositorio:Addi. Archivo Digital para la Docencia y la Investigación
OAI Identifier:oai:addi.ehu.eus:10810/64856
Acceso en línea:http://hdl.handle.net/10810/64856
Access Level:acceso abierto
Palabra clave:linezolid
population pharmacokinetics
critically ill
continuous renal replacement therapies
pharmacokinetic/pharmacodynamics
continuous infusion
id ES_3073c8e9b4c14a9053d8eaa4bcdabd5e
oai_identifier_str oai:addi.ehu.eus:10810/64856
network_acronym_str ES
network_name_str España
repository_id_str
spelling Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing RecommendationSoraluce Olañeta, AmaiaBarrasa González, HelenaAsín-Prieto, EduardoSánchez Izquierdo, José ÁngelMaynar, JavierIsla Ruiz, ArantxazuRodríguez Gascón, Alicialinezolidpopulation pharmacokineticscritically illcontinuous renal replacement therapiespharmacokinetic/pharmacodynamicscontinuous infusionAntimicrobial treatment in critically ill patients remains challenging. The aim of this study was to develop a population pharmacokinetic model for linezolid in critically ill patients and to evaluate the adequacy of current dosing recommendation (600 mg/12 h). Forty inpatients were included, 23 of whom were subjected to continuous renal replacement therapies (CRRT). Blood and effluent samples were drawn after linezolid administration at defined time points, and linezolid levels were measured. A population pharmacokinetic model was developed, using NONMEM 7.3. The percentage of patients that achieved the pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated (AUC24/MIC > 80 and 100% T>MIC). A two‐compartment model best described the pharmacokinetics of linezolid. Elimination was conditioned by the creatinine clearance and by the extra‐corporeal clearance if the patient was subjected to CRRT. For most patients, the standard dose of linezolid did not cover infections caused by pathogens with MIC ≥This research was funded by Pfizer (012 ASPIRE EUMRSA _ Pharmacokinetic pharmacodynamic study of linezolid in critically ill septic patients undergoing continuous hemodiafiltration) and by the University of the Basque Country UPV/EHU (PPG17/65 and GIU17/32).MDPI202420242020info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10810/64856reponame:Addi. Archivo Digital para la Docencia y la Investigacióninstname:Universidad del País VascoIngléshttps://www.mdpi.com/1999-4923/12/1/54info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).oai:addi.ehu.eus:10810/648562026-06-18T09:23:17Z
dc.title.none.fl_str_mv Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
title Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
spellingShingle Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
Soraluce Olañeta, Amaia
linezolid
population pharmacokinetics
critically ill
continuous renal replacement therapies
pharmacokinetic/pharmacodynamics
continuous infusion
title_short Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
title_full Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
title_fullStr Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
title_full_unstemmed Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
title_sort Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
dc.creator.none.fl_str_mv Soraluce Olañeta, Amaia
Barrasa González, Helena
Asín-Prieto, Eduardo
Sánchez Izquierdo, José Ángel
Maynar, Javier
Isla Ruiz, Arantxazu
Rodríguez Gascón, Alicia
author Soraluce Olañeta, Amaia
author_facet Soraluce Olañeta, Amaia
Barrasa González, Helena
Asín-Prieto, Eduardo
Sánchez Izquierdo, José Ángel
Maynar, Javier
Isla Ruiz, Arantxazu
Rodríguez Gascón, Alicia
author_role author
author2 Barrasa González, Helena
Asín-Prieto, Eduardo
Sánchez Izquierdo, José Ángel
Maynar, Javier
Isla Ruiz, Arantxazu
Rodríguez Gascón, Alicia
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv linezolid
population pharmacokinetics
critically ill
continuous renal replacement therapies
pharmacokinetic/pharmacodynamics
continuous infusion
topic linezolid
population pharmacokinetics
critically ill
continuous renal replacement therapies
pharmacokinetic/pharmacodynamics
continuous infusion
description Antimicrobial treatment in critically ill patients remains challenging. The aim of this study was to develop a population pharmacokinetic model for linezolid in critically ill patients and to evaluate the adequacy of current dosing recommendation (600 mg/12 h). Forty inpatients were included, 23 of whom were subjected to continuous renal replacement therapies (CRRT). Blood and effluent samples were drawn after linezolid administration at defined time points, and linezolid levels were measured. A population pharmacokinetic model was developed, using NONMEM 7.3. The percentage of patients that achieved the pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated (AUC24/MIC > 80 and 100% T>MIC). A two‐compartment model best described the pharmacokinetics of linezolid. Elimination was conditioned by the creatinine clearance and by the extra‐corporeal clearance if the patient was subjected to CRRT. For most patients, the standard dose of linezolid did not cover infections caused by pathogens with MIC ≥
publishDate 2020
dc.date.none.fl_str_mv 2020
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10810/64856
url http://hdl.handle.net/10810/64856
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://www.mdpi.com/1999-4923/12/1/54
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Addi. Archivo Digital para la Docencia y la Investigación
instname:Universidad del País Vasco
instname_str Universidad del País Vasco
reponame_str Addi. Archivo Digital para la Docencia y la Investigación
collection Addi. Archivo Digital para la Docencia y la Investigación
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405545728835584
score 15,301603

Similares en LA Referencia